KRYS - Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB
2024-05-15 08:08:16 ET
Summary
- Krystal Biotech is a promising biotech stock with strong revenue growth after the approval of its flagship product, VYJUVEK.
- VYJUVEK is a topical gene therapy for treating dystrophic epidermolysis bullosa and has the potential to generate substantial revenue.
- VYJUVEK’s weekly application ensures repeated revenue streams, with strong early adoption and high patient compliance.
- Its product pipeline in dermatology, respiratory, oncology, and ophthalmology could bring in additional revenue verticals.
- With a robust financial position and no debt, KRYS’s valuation appears reasonable, making it a "buy" at these levels.
...
Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB